Patents by Inventor Antje Danielczyk

Antje Danielczyk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-MUC1 antibody-drug conjugate
    Patent number: 12479926
    Abstract: The present disclosure relates to antibody drug conjugates directed against the cancer antigen MUC1. In particular, an antibody with improved antigen binding was obtained by deleting a glycosylation site in the CDR-H2 of a known anti-MUC1 antibody. The conjugates consist of exatecan derivatives coupled to the anti MUC1 antibodies.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: November 25, 2025
    Assignee: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna Gellert, Anke Flechner, Doreen Weigelt, Antje Danielczyk, Akiko Nagase
  • Humanized antibodies against Lewis Y
    Patent number: 12415864
    Abstract: The present invention pertains to humanized anti-Lewis Y antibodies which specifically bind to Lewis Y and do not show any cross-reactivity. Especially, the humanized anti-Lewis Y antibodies do not bind to Lewis b or any other blood group carbohydrate antigen. In particular, the present invention is directed to humanized anti-Lewis Y antibodies which are useful in the treatment of cancer.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: September 16, 2025
    Assignee: Pentixapharm AG
    Inventors: Antje Danielczyk, Johanna Gellert, Anke Flechner, Patrik Kehler
  • ANTI-MUC1 ANTIBODY
    Publication number: 20250257149
    Abstract: The present invention pertains to novel antibodies directed against the cancer antigen MUC1. In particular, an antibody with improved antigen binding was obtained by deleting a glycosylation site in the CDR-H2 of a known anti-MUC1 antibody.
    Type: Application
    Filed: February 13, 2025
    Publication date: August 14, 2025
    Applicant: GLYCOTOPE GMBH
    Inventors: Johanna GELLERT, Anke FLECHNER, Doreen WEIGELT, Antje DANIELCZYK
  • ANTI-MUC1 ANTIBODY-DRUG CONJUGATE
    Publication number: 20250223375
    Abstract: The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.
    Type: Application
    Filed: March 26, 2025
    Publication date: July 10, 2025
    Applicant: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna GELLERT, Anke FLECHNER, Doreen WEIGELT, Antje DANIELCZYK, Akiko NAGASE
  • Anti-MUC1 antibody
    Patent number: 12297289
    Abstract: The present disclosure pertains to novel antibodies directed against the cancer antigen MUC1. In particular, an antibody with improved antigen binding was obtained by deleting a glycosylation site in the CDR-H2 of a known anti-MUC1 antibody.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: May 13, 2025
    Assignee: GLYCOTOPE GMBH
    Inventors: Johanna Gellert, Anke Flechner, Doreen Weigelt, Antje Danielczyk
  • Anti-MUC1 antibody-drug conjugate
    Patent number: 12291577
    Abstract: The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.
    Type: Grant
    Filed: July 10, 2023
    Date of Patent: May 6, 2025
    Assignee: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna Gellert, Anke Flechner, Doreen Weigelt, Antje Danielczyk, Akiko Nagase
  • ANTIBODIES AGAINST LYPD3
    Publication number: 20250074999
    Abstract: The present invention pertains to anti-LYPD3 antibodies which bind LYPD3 in an O-glycosylation-dependent manner. Thereby, the antibodies are specific for tumor-associated LYPD3. The invention further provides pharmaceutical compositions containing said anti-LYPD3 antibodies and their use in cancer treatment.
    Type: Application
    Filed: March 16, 2023
    Publication date: March 6, 2025
    Inventors: Johanna GELLERT, Antje DANIELCZYK, Patrik KEHLER, Anika JÄKEL, Sven BAHRKE, Timo LISCHKE, Christoph GOLETZ, Anke FLECHNER, Lars STÖCKL, Stephanie GURKA
  • Anti-MUC1 antibody-drug conjugate
    Patent number: 11872289
    Abstract: The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.
    Type: Grant
    Filed: August 1, 2022
    Date of Patent: January 16, 2024
    Assignee: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna Gellert, Anke Flechner, Doreen Weigelt, Antje Danielczyk, Akiko Nagase
  • ANTI-MUC1 ANTIBODY-DRUG CONJUGATE
    Publication number: 20230372520
    Abstract: The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.
    Type: Application
    Filed: July 10, 2023
    Publication date: November 23, 2023
    Applicant: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna GELLERT, Anke FLECHNER, Doreen WEIGELT, Antje DANIELCZYK, Akiko NAGASE
  • HUMANIZED ANTIBODIES AGAINST LEWIS Y
    Publication number: 20230235076
    Abstract: The present invention pertains to humanized anti-Lewis Y antibodies which specifically bind to Lewis Y and do not show any cross-reactivity. Especially, the humanized anti-Lewis Y antibodies do not bind to Lewis b or any other blood group carbohydrate antigen. In particular, the present invention is directed to humanized anti-Lewis Y antibodies which are useful in the treatment of cancer.
    Type: Application
    Filed: June 29, 2021
    Publication date: July 27, 2023
    Inventors: Antje DANIELCZYK, Johanna GELLERT, Anke FLECHNER, Patrik KEHLER
  • ANTI-MUC1 ANTIBODY-DRUG CONJUGATE
    Publication number: 20230139769
    Abstract: The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.
    Type: Application
    Filed: August 1, 2022
    Publication date: May 4, 2023
    Applicant: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna GELLERT, Anke FLECHNER, Doreen WEIGELT, Antje DANIELCZYK, Akiko NAGASE
  • ANTI-MUC1 ANTIBODY
    Publication number: 20210221910
    Abstract: The present disclosure pertains to novel antibodies directed against the cancer antigen MUC1. In particular, an antibody with improved antigen binding was obtained by deleting a glycosylation site in the CDR-H2 of a known anti-MUC1 antibody.
    Type: Application
    Filed: May 17, 2019
    Publication date: July 22, 2021
    Applicant: GLYCOTOPE GMBH
    Inventors: Johanna GELLERT, Anke FLECHNER, Doreen WEIGELT, Antje DANIELCZYK
  • ANTI-MUC1 ANTIBODY-DRUG CONJUGATE
    Publication number: 20210187118
    Abstract: The present disclosure relates to antibody drug conjugates directed against the cancer antigen MUC1. In particular, an antibody with improved antigen binding was obtained by deleting a glycosylation site in the CDR-H2 of a known anti-MUC1 antibody. The conjugates consist of exatecan derivatives coupled to the anti MUC1 antibodies.
    Type: Application
    Filed: May 17, 2019
    Publication date: June 24, 2021
    Applicant: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna GELLERT, Anke FLECHNER, Doreen WEIGELT, Antje DANIELCZYK, Akiko NAGASE
  • Fusion Protein Constructs Comprising an Anti-MUC1 Antibody and IL-15
    Publication number: 20210107961
    Abstract: The present invention pertains to fusion protein constructs comprising an antibody against the cancer antigen MUC1 and IL-15. In particular, the fusion protein constructs activate NK cells and T cells at the cancer site.
    Type: Application
    Filed: March 1, 2019
    Publication date: April 15, 2021
    Inventors: Johanna GELLERT, Patrik KEHLER, Anika JÄKEL, Laura DIX, Antje DANIELCZYK, Steffen GOLETZ
  • PD-L1 AND TA-MUC1 ANTIBODIES
    Publication number: 20200148785
    Abstract: The present invention relates to an antibody which effects enhanced T cell activation in comparison to a reference antibody being glycosylated including more than 80% core-fucosylation and wherein T cell activation is effected by an antibody characterized by enhanced binding to Fc#RIIIa. Said antibody is glycosylated, but essentially lacks core-fucosylation.
    Type: Application
    Filed: March 28, 2018
    Publication date: May 14, 2020
    Inventors: Patrik Kehler, Steffen Goletz, Antje Danielczyk, Johanna Ruehmann, Christoph Goletz
  • MULTISPECIFIC ANTIBODY CONSTRUCTS BINDING TO MUC1 AND CD3
    Publication number: 20200131275
    Abstract: The present invention pertains to multispecific antibody constructs directed against the cancer antigen MUC1 and the T cells antigen CD3. In particular, the multispecific antibody constructs recruit T cells to the cancer site. The design of the multispecific antibody constructs show strong antigen binding and high T cell activation.
    Type: Application
    Filed: March 27, 2018
    Publication date: April 30, 2020
    Inventors: Steffen GOLETZ, Patrik KEHLER, Johanna GELLERT, Antje DANIELCZYK, Anika JÄKEL
  • HUMANIZED ANTI-CD40 ANTIBODIES
    Publication number: 20200087410
    Abstract: The present invention pertains to humanized anti-CD40 antibodies having antigen binding properties similar to those of the parent chimeric anti-CD40 antibody and increased Fc? receptor binding affinities. In particular, the present invention is directed to humanized anti-CD40 antibodies which are useful in the treatment of cancer, infections and immunodeficiencies.
    Type: Application
    Filed: March 27, 2018
    Publication date: March 19, 2020
    Applicant: Glycotope GmbH
    Inventors: Steffen GOLETZ, Antje DANIELCZYK, Anja LOFFLER, Doreen WEIGELT, Patrick KEHLER
  • USE OF HUMAN CELLS OF MYELOID LEUKAEMIA ORIGIN FOR EXPRESSION OF ANTIBODIES
    Publication number: 20190359731
    Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.
    Type: Application
    Filed: April 5, 2019
    Publication date: November 28, 2019
    Inventors: Steffen GOLETZ, Antje DANIELCZYK, Hans BAUMEISTER, Renate STAHN, Anja LOEFFLER, Lars STOECKL
  • Use of human cells of myeloid leukemia origin for expression of antibodies
    Patent number: 10280230
    Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: May 7, 2019
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Antje Danielczyk, Hans Baumeister, Renate Stahn, Anja Loeffler, Lars Stoeckl
  • Eukaryotic expression vectors comprising regulatory elements of the globin gene clusters
    Patent number: 10184135
    Abstract: The present invention pertains to the field of recombinant protein production. Novel expression cassettes comprising elements of the human globin gene clusters are provided which show enhanced expression rates of proteins or polypeptides of interest.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: January 22, 2019
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Doreen Jahn, Antje Danielczyk